Neoplasia 2 Flashcards

1
Q

Describe neoplasia.

A

-result of abnormality in cell cycle
-unlimited prolif
>irreversible unregulated autonomous
-result of heritable change in DNA of tumor cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe what neoplasms often have mutations in.

A
  1. Defective DNA repair
  2. Self sufficient growth signal
  3. Insensitivity to growth inhibition
  4. Evasion of apoptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe senescence.

A

-resp to DNA damage, oxidative stress, telomere shortening, prolif cell undergo permanent arrest in G1 phase
-re-expression of telomerase = imp role in escape of tumor cells from senescence & immortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe apoptosis VS autophagy.

A
  1. Apoptosis
    -normal & pathogenic
    -signals release cytochrome C from mitochondria = capases
    -cancer cell require resistance to apoptosis by functional inactivation of p53 gene
  2. Autophagy
    -degrade cell own organelle within auto phagosome
    -paradoxical role in tumor growth
    -autophagy suppressed in many tumors & others have inc autophagy to enhance tumor cell survival under dec nutrient avail during therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe defective DNA repair.

A

-abnormal cell cycle checkpoint
-abnormal resp to DNA damage
-lead to genetic instability -> more mutation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe self sufficient growth signals.

A
  1. Proto oncogene
    -normal
    -prod are regulator of cell prolif & growth
  2. Oncogene
    -prod are oncoprotein = no regulatory elements
    -expression = inc uncontrolled cell prolif (division)
    -mutation dominant
    -inhibit cell death
    -dec cell differentiation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe oncogene example.

A

CKIT
-proto oncogene ckit encodes KIT = receptor tyrosine kinase w GF ligand
-mutation of ckit into oncogene = receptor always active w/o GF binding
-mutation in 20% K9 mast cell tumor
-production of:
>GF
>receptor for GF
>protein directly control entry of cells into cell cycle
*tyrosine kinase inhibitor used to treat K9 mast cell tumor ‘palladia’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe insensitivity to growth inhibition signals.

A
  1. Tumor suppressor gene
    -inhibit cell prolif
    -absent = cell insensitive to growth inhibition signal
  2. Mutations are recessive
    -need 2 independent mutations
    -inherited in germ line
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe an example of tumor suppressor gene.

A

P53
-encode p53 = DNA binding protein that stim genes involved in arresting cell cycle & stim DNA repair & apoptosis
-guardian of genome
-ineffective p53 = genetic instability
-mutation common in domestic animal
-inc tendency for DNA mutation & other genetic change to occur during cell division

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the evasion of apoptosis.

A
  1. Normal trigger for apoptosis
    -DNA damage
    -loss of nutrient/GF
    -binding of death factor
    -cytotoxic lymphocyte
  2. Malignant cell better than benign cell
  3. Mutation dom or recessive
    -ex: overexpression of Bcl2 = reduce apoptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe the therapeutic implications of the molecular basis of cancer.

A

-cancer treated using cytotoxic drugs or radiation therapy = neither discriminate normal VS tumor cell -> non selective cell killing has side effects
-mutation & other defects used to stratify patients for treatment or prognostic purposes
-WGS (whole genome seq) = ID all mutation in tumor & target specific driver mutations
-individualized cancer therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe clonicity in neoplasms.

A

-neoplasms are clonal = evolution of malignancy
>become heterogenous over time bc genetic instability
-progression/transformation:
A) dysplastic -> neoplastic
B) benign -> malignant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe tumor cell progression & effect of therapy.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe invasion.

A

in situ = not invaded BM yet (cancer at diff stages
-malignant tumor dont respect anatomic boundaries
>invasion is a prerequisite for metastasis
-invading cells must:
1. Overcome passive growth (mechanical) pressure: loss of contact inhibition
2. Loosen cell junctions
3. Penetrate BM & ECM via enzymatic destruction (collagenase, matrix metalloproteinases)
4. Migrate actively - stim by GF & cleavage prod of ECM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe epithelial mesenchymal transition.

A
  1. Loss of intercellular adhesion structures
  2. Enhanced expression of proteases
  3. Acquisition of migratory capabilities
  4. Reduced expression of epi cytokeratins & de novo expression of vimentin (mesenchymal cell marker)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe lymphovascular invasion (LVI).

A

-neoplastic cells gaining access to lymphatics or blood vessels
-criterion of malignancy

17
Q

Describe the metastatic cascade - tumor dissemination.

A

*most die from turbulence, oxygen toxicity, leukocyte attack, unfavorable nutritional environment, lack of GF
1. Tumor grows locally
2. Genetic & epigenetic changes -> metastasize
>lymph vessels
>blood vessels
>dissemination thruout bod cavity

18
Q

Describe tumor stromal interactions.

A

*stroma = extracellular CT (proteins & glycoproteins like collagen) in proteoglycans (ECM)
-tumor = tumor cells + non neoplastic supporting stroma (ECM, blood vessel, fibroblast, inflam cells, immune cells)
-tumor cells & stroma = mutual control
>stim angiogenesis *

19
Q

Describe tumor angiogenesis.

A

-w/o new blood vessels tumor are limited to max diameter of 1-2mm
-tumor recruit endothelial cells & promote migration & growth = angiogenic factors like VEGF (vascular endothelial GF)
-endothelial cells of new vessels make other GF that stim growth of tumor cells
-new tumor blood vessels not norm

20
Q

Describe the 3 pathways of spread (metastasis).

A
  1. Transcoelomic
    -body cavity & surface of organs
    -fewer anatomic barriers to overcome
    -mesotheliomas, ovarian adenocarinomas
    -diff to treat & fatal
  2. Hematogenous
    -sarcomas
    -invasion of veins
  3. Lymphatic
    -carcinomas
    -pattern by route of lymph drainage
    -lymph spread not orderly = regional LN not first step but indicate neoplasia is potentially widely systemic
21
Q

Describe other types of metastasis.

A
  1. Hematogenous/lymphatic (lymphovascular)
    -metastasis arrest in first capillary bed encountered
    -LUNG for tumors *
    -liver for enteric tumors
  2. Other patterns = organotropism
    -bone metastasis -> prostate & mammary carcinoma*
    -pulmonary carcinoma & digit metastasis in cat
  3. Explanations
    -express adhesion mol whose ligands are organ specific
    -liberation of chemo attractant by target organ
  4. Some tissue un permissive to metastasis = skeletal muscle
22
Q

Describe transmissible tumors - clonally.

A

*spread beyond OG host via physical transplantation following direct physical contact between animals of same species
*neoplastic cells transplanted & grow like graft (xeno)
1. TV (transmissible venereal tumor) in dogs -> oral
2. Devil facial tumor disease of Tasmanian devil
-mouth & face
-fighting/facial biting
3. Virtual induced tumors
-papilloma

23
Q

Describe tumor immunity.

A

*innate & adaptive immunity
Ex: K9 histiocytoma = host mediated spontaneous tumor regression via lymphocytes
-proteins & carbs expressed on tumor cell surface
-expressed by normal cells, some are tumor specific
>cell prod encoded by mutated genes
>antigens derived from oncogenic viruses
>embryonic antigens in primitive (undiff) cells
-can be exploited for diagnostics & therapeutics
>CA125 antigen in human ovarian carcinoma - radiolabeled Ab to detect metastases w PET/CT
>immunotherapy for human breast cancer
*K9 prostatic specific esterase (CPSE) - bio marker to use as preventative screening for prostate health

24
Q

Describe antitumor effector mechanisms.

A

-immunosurveillance = IS capable of recog Ag expressed on tumor cell & attack
-immunosuppressed ppl have greater prevalence of neoplasia
-2 types of IR determined by host & tumor Ag
1) innate IR
>1st line defense
>NK, Mac
>dont require Ag-specific priming
2) adaptive IR
>DC to capture tumor Ag & display on MHC
>cell mediated - most effective anti tumor defense (CD8 T cell)
>humoral - T helper & B cells

25
Q

Describe the evasion of the IR.

A

-loss or mask of tumor specific Ag
-altered MHC expression
-tolerance - esp if Ag is shared w normal tissue
-immunosuppression - Fas ligand stim apoptosis of binding T cells

26
Q

Describe tumor immunotherapy.

A
  1. attack only tumor cell & not normal tissue
    >dec/elim need to use cytotoxic chemo agents that indiscriminate target normal & neoplastic cells
  2. antitumor lymphocytes - in vitro incubation w IL2
  3. melanoma vaccine - (dogs) stim IR against human tyrosinase - Ab against human protein formed that attack K9 melanocytes
  4. Block activity of tumor associated macs & T reg cells ***
27
Q

Describe macrophages phenotype & cancer.

A

-M1 & M2 = key regulator during cancer progression
-neoplastic cells promote polarization of M1 to M2 macs (TAMS) - poor prog in tumors
>prognostic bio marker ?
>therapeutic target ?
-M2 =
>promote motility of cancer cells in invasion areas
>promote metastasis in stromal & perivascular areas
>stim angiogenesis in avascular & peri necrotic hypoxic areas

TAMS = tumor associated macs